Review Article
Update on Chemotherapy in the Treatment of Urothelial Carcinoma
Table 1
Second-line single agent chemotherapy trials in advanced urothelial carcinoma.
| Reference | Agent | Subjects | Response rate (%) | Survival (months) |
| Witte et al. [4] | Ifosfamide | 56 | 20 | 5.5 | McCaffrey et al. [5] | Docetaxel | 30 | 13 | 9 | Lorusso et al. [6] | Gemcitabine | 35 | 23 | 5 | Albers et al. [7] | Gemcitabine | 30 | 11 | 8.7 | Vaughn et al. [8] | Paclitaxel | 31 | 10 | 7.2 | Joly et al. [9] | Paclitaxel | 45 | 9 | 7 | Sweeney et al. [10] | Pemetrexed | 47 | 28 | 9.6 | Galsky et al. [11] | Pemetrexed | 13 | 8 | Not reported | Dreicer et al. [12] | Ixabepilone | 45 | 12 | 8 | Sridhar et al. [13] | Nab-paclitaxel | 48 | 33 | Not reported | Bellmunt et al. [14] | Vinflunine | 307 | 9 | 6.9 |
|
|